Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRockwell Medical Inc

Rockwell Medical Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
8.09 USD 1.18 ( 17.08%)
Last update at 2026-11-03T21:00:00Z
VOLUME
61978
Market Cap
54.27M

Momentum Score

…

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.45
Low
8.24
High
52 Week Price Range
1.16
Low
6.24
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Rockwell Medical is a specialty pharmaceutical company commercializing an iron-replacement therapy for dialysis-dependent patients. Long-term growth drivers include wider adoption in dialysis centers, possible geographic or indication expansion, and recurring demand from a chronic patient population, which may appeal to investors seeking exposure to a focused product addressing a clear clinical need.

Principal risks are dependence on a single product with concentrated revenue, competition and reimbursement pressure versus intravenous iron, limited commercial scale that may require further financing, and regulatory or adoption hurdles.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.91
Dividend Yield
-
Revenue TTM
86.62M
Revenue Per Share
3.32
Gross Profit TTM
4.08M
Debt / Equity
0.63
ROE
-47.68%
Net Debt
4.46M
ROCE
-47.22%
Diluted EPS TTM
-0.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -18.68M -32.67M -30.89M -34.13M -32.13M
Net income -20.58M -35.03M -31.93M -31.08M -32.13M
Selling general administrative 15.64M 15.35M 16.18M 21.00M 23.08M
Selling and marketing expenses 2.09M 5.73M 7.87M 9.05M -
Gross profit 4.08M -2.42M 2.73M 2.84M -1.58M
Reconciled depreciation 2.59M 2.52M 2.29M 2.65M 0.65M
Ebit -16.78M -30.34M -28.42M -34.10M -31.84M
Ebitda -16.75M -27.80M -26.73M -34.13M -31.19M
Depreciation and amortization 0.03M 2.54M 1.69M -0.03M 0.65M
Non operating income net other - - -2.47M 0.40M 0.31M
Operating income -16.78M -30.34M -28.42M -34.10M -32.44M
Other operating expenses 89.59M 92.27M 90.62M 95.40M 94.80M
Interest expense 1.94M 2.36M 1.88M 0.00M 0.00M
Interest income 0.03M 0.02M 0.24M 0.37M 0.54M
Net interest income -1.90M -2.34M -1.64M 0.37M 0.54M
Non recurring - - - 0.43M 2.13M
Income tax expense 1.90M 2.36M 1.04M -3.05M 0.31M
Total revenue 72.81M 61.93M 62.20M 61.30M 63.39M
Total operating expenses 20.86M 27.92M 31.14M 36.93M 29.82M
Cost of revenue 68.73M 64.35M 59.47M 58.46M 64.97M
Total other income expense net -1.90M -2.34M -2.47M -0.03M -1.25M
Net income from continuing ops -18.68M -32.67M -30.89M -34.13M -32.13M
Net income applicable to common shares -18.68M -32.67M -30.89M -34.13M -32.13M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 52.17M 46.63M 48.57M 77.75M 44.32M
Intangible assets 10.76M - - - 0.00M
Other current assets 1.06M 1.75M 2.86M 2.71M 2.98M
Total liab 30.88M 32.53M 46.04M 43.58M 24.00M
Total stockholder equity 21.29M 14.11M 2.54M 34.17M 20.32M
Other current liab 9.89M 7.70M 5.09M 5.14M 4.81M
Common stock 0.00M 0.00M 0.01M 0.01M 0.01M
Capital stock 0.00M 0.00M 0.01M 0.01M 0.01M
Retained earnings -397.20M -388.76M -370.08M -337.41M -306.52M
Other liab - 2.61M 6.00M 8.02M 9.84M
Good will 0.92M 0.92M 0.92M 0.92M 0.92M
Other assets - 13.82M 2.14M 4.72M 0.88M
Cash 8.98M 21.49M 13.28M 48.68M 11.79M
Total current liabilities 16.64M 17.69M 20.97M 12.79M 12.37M
Current deferred revenue 0.05M 1.80M 2.31M 2.33M 2.29M
Net debt 4.46M -5.13M 15.62M -24.75M -7.76M
Short term debt 2.18M 4.14M 9.82M 1.17M 2.26M
Short long term debt 0.24M 2.13M 7.82M - 0.76M
Short long term debt total 13.44M 16.36M 28.89M 23.94M 4.04M
Other stockholder equity 418.49M 402.70M 372.55M 371.51M 326.78M
Property plant equipment - 8.61M 10.22M 5.55M 2.87M
Total current assets 28.77M 35.31M 35.29M 69.47M 36.87M
Net tangible assets - 13.19M 1.61M 33.25M 19.40M
Short term investments 1.95M 11.39M 9.16M 10.00M 14.25M
Net receivables 10.90M 6.26M 5.91M 4.17M 4.20M
Long term debt 8.29M 7.55M 13.19M 20.95M -
Inventory 5.87M 5.81M 4.08M 3.91M 3.65M
Accounts payable 4.52M 4.05M 3.74M 4.16M 3.02M
Accumulated other comprehensive income -0.00M 0.16M 0.05M 0.06M 0.05M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -337.41M -306.52M
Non currrent assets other 0.70M 1.80M 2.14M 1.80M 0.88M
Non current assets total 23.40M 11.32M 13.29M 8.28M 7.44M
Capital lease obligations 4.90M 6.67M 7.89M 2.99M 3.27M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.40M 0.31M 4.26M 38.27M 33.90M
Change to liabilities -3.51M -2.45M -0.75M -3.73M -2.12M
Total cashflows from investing activities -2.40M 0.31M 3.21M -4.75M 12.72M
Net borrowings -13.19M -2.28M 21.74M -1.15M -1.15M
Total cash from financing activities 16.63M -2.18M 63.32M 21.08M 22.00M
Change to operating activities 3.35M 0.00M -0.93M -1.34M 0.15M
Net income -18.68M -32.67M -30.89M -34.13M -32.13M
Change in cash -3.18M -35.40M 36.89M -10.92M 14.31M
Begin period cash flow 13.28M 48.68M 11.79M 22.71M 8.41M
End period cash flow 10.10M 13.28M 48.68M 11.79M 22.71M
Total cash from operating activities -17.41M -33.53M -29.64M -27.25M -20.42M
Issuance of capital stock 30.02M 0.11M 45.47M 24.16M 22.00M
Depreciation 2.59M 2.52M 2.29M 2.65M 0.65M
Other cashflows from investing activities - - - -42.43M -20.43M
Dividends paid - - 22.50M 0.15M -
Change to inventory -2.10M -0.66M -1.31M 0.32M -0.84M
Change to account receivables -0.35M -1.74M 0.03M 2.78M -0.62M
Sale purchase of stock 0.00M -0.01M -0.02M -0.28M 22.00M
Other cashflows from financing activities -0.19M 0.31M 41.12M -1.50M 0.00M
Change to netincome 0.92M 1.10M 1.62M 6.23M 14.50M
Capital expenditures 0.28M 0.52M 1.05M 1.34M 0.99M
Cash flows other operating - - -1.51M -0.14M -3.44M
Cash and cash equivalents changes - - 36.89M -10.96M 14.31M
Change in working capital -2.61M -4.84M -2.96M -1.98M -3.43M
Stock based compensation 0.32M 0.94M 0.47M 4.95M 4.39M
Other non cash items 0.97M 0.37M 0.29M 1.24M 1.10M
Free cash flow -17.70M -34.06M -30.69M -28.59M -21.41M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RMTI
Rockwell Medical Inc		 1.18
17.08%		 8.09 - - 0.56 2.20 0.59 -10.53
MKKGY
Merck KGaA ADR		 -0.50
1.48%		 33.21 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.26
0.75%		 167.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.75 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -0.91
2.17%		 41.09 - 10.66 0.01 1.16 2.94 23.11

Profile*

Rockwell Medical Inc

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

30142 South Wixom road, Wixom, MI, United States, 48393

248 960 9009

https://www.rockwellmed.com

237

Name Title Year Born
Dr. Mark Strobeck Ph.D. Pres, CEO & Director 1971
Mr. Paul E. McGarry SVP of Fin. & Chief Accounting Officer 1968
Ms. Megan C. Timmins Sr. VP, Gen. Counsel & Corp. Sec. 1973
Mr. James A. McCarthy Sr. VP of Bus. & Corp. Devel. NA
Mr. Timothy T. Chole Sr. VP of Sales & Marketing NA
Dr. Marc L. Hoffman M.D. Chief Medical Officer 1961
Ms. Heather R. Hunter Sr. VP & Chief Corp. Affairs Officer NA
Mr. David J. Kull Sec. 1968
Mr. Jason Finkelstein Investor Relations Representative NA
Dr. Mark Strobeck Ph.D. President, CEO & Director 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…